November 05, 2025

SGLT2 Inhibitors Reduce Lung Cancer Surgery

Patients with diabetes taking SGLT2 inhibitors show fewer lung surgeries over 10 years.

Conexiant

September 26, 2023

Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma

Discover the latest insights into sarcoma and rare adult solid cancers from the recent ESMO Sarcoma and Rare Cancers Congress, underlining the significance of multidisciplinary approaches and research efforts. Voices from young oncologists shed light on the pressing need for qualified resources. #ESMO2023

The ASCO Post

January 25, 2023

Communicating Prognosis: A Core Competency of Patient-Centered Oncology Care

Physicians tackle challenges discussing prognosis due to inadequate formal training and the discomfort of the conversations. Redefining prognosis can alleviate patients' fears about the future. Click to learn evidence-based tools for better communication.

The ASCO Post

January 25, 2023

Expert Point of View: Bita Fakhri, MD, MPH

Renowned Assistant Professor of Medicine at Stanford Medicine, Dr. Bita Fakhri, sheds light on the ongoing phase III CLL13 trial and the potential impact of adding an anti-CD20 monoclonal antibody to venetoclax and ibrutinib. She emphasizes the critical need for longer follow-up data to assess its effectiveness.

The ASCO Post

July 11, 2024

Association of Genetic Risk for Prostate Cancer With Early Prostate Cancer Death

A recent cohort study found that men at a higher genetic risk for prostate cancer were more likely to experience early death from prostate cancer compared to men with a lower genetic risk for the dise...

The ASCO Post

December 19, 2023

W. Kimryn Rathmell, MD, PhD, Begins Work as 17th Director of the NCI

On December 18, W. Kimryn Rathmell, MD, PhD, began her work as the 17th Director of the National Cancer Institute. 

The ASCO Post

October 25, 2023

ASCO Response to Drug Shortages Request for Information

The Association for Clinical Oncology (ASCO) responded to a bicameral Request for Information (RFI) on the underlying factors driving drug shortages. The Association’s comments highlighted the impact ...

The ASCO Post

February 06, 2025

Welcome From the Director of The Tisch Cancer Institute

With this 2025 Specialty Report, we are pleased to share how we are pushing the boundaries of cancer discovery and propelling the development of novel therapies for optimal patient outcomes. With innovative thinking and access to state-of-the-art technologies, our clinicians and scientists are designing and collaborating on projects focused on unraveling cancer behavior and countering its ability to thrive.

Mount Sinai New York

August 17, 2023

Ruxolitinib Demonstrates Clinical Activity in a Phase II Trial of Chronic Myelomonocytic Leukemia

In a phase II trial, treatment with the JAK2 inhibitor ruxolitinib resulted in clinical activity in two-thirds of patients with chronic myelomonocytic leukemia with splenomegaly or an otherwise high d...

The ASCO Post